OncoMatch/Clinical Trials/NCT06120491
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Is NCT06120491 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Saruparib and Abiraterone Acetate for metastatic castration-sensitive prostate cancer.
Treatment: Saruparib · Abiraterone Acetate · Darolutamide · Enzalutamide — The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen deprivation therapy (GnRH analogue) — castration-sensitive
Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting 14 days and < 4 months prior to randomisation.
Must have received: orchiectomy — castration-sensitive
Participant...has undergone bilateral orchiectomy starting 14 days and < 4 months prior to randomisation.
Cannot have received: anticancer pharmacotherapy or surgery for metastatic prostate cancer
Exception: exceptions
Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions.
Cannot have received: blood product support or growth factor support
Prior treatment within 14 days with blood product support or growth factor support.
Lab requirements
Blood counts
Adequate organ and bone marrow function as described in study protocol.
Kidney function
Adequate organ and bone marrow function as described in study protocol.
Liver function
Adequate organ and bone marrow function as described in study protocol.
Cardiac function
Cardiac criteria, including history of arrhythmia and cardiovascular disease [excluded].
Adequate organ and bone marrow function as described in study protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Chandler, Arizona
- Research Site · Gilbert, Arizona
- Research Site · Phoenix, Arizona
- Research Site · Tucson, Arizona
- Research Site · Little Rock, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify